vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and SMITH & WESSON BRANDS, INC. (SWBI). Click either name above to swap in a different company.
AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $124.7M, roughly 1.5× SMITH & WESSON BRANDS, INC.). SMITH & WESSON BRANDS, INC. runs the higher net margin — 1.5% vs 0.9%, a 0.6% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs -3.9%). SMITH & WESSON BRANDS, INC. produced more free cash flow last quarter ($16.3M vs $16.0M). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs -4.8%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
FOLD vs SWBI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $185.2M | $124.7M |
| Net Profit | $1.7M | $1.9M |
| Gross Margin | 85.7% | 24.3% |
| Operating Margin | 8.6% | 3.3% |
| Net Margin | 0.9% | 1.5% |
| Revenue YoY | 23.7% | -3.9% |
| Net Profit YoY | -88.5% | -53.6% |
| EPS (diluted) | $0.00 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.2M | $124.7M | ||
| Q3 25 | $169.1M | $85.1M | ||
| Q2 25 | $154.7M | $140.8M | ||
| Q1 25 | $125.2M | $115.9M | ||
| Q4 24 | $149.7M | $129.7M | ||
| Q3 24 | $141.5M | $88.3M | ||
| Q2 24 | $126.7M | $159.1M | ||
| Q1 24 | $110.4M | $137.5M |
| Q4 25 | $1.7M | $1.9M | ||
| Q3 25 | $17.3M | $-3.4M | ||
| Q2 25 | $-24.4M | $8.6M | ||
| Q1 25 | $-21.7M | $2.1M | ||
| Q4 24 | $14.7M | $4.5M | ||
| Q3 24 | $-6.7M | $-1.9M | ||
| Q2 24 | $-15.7M | $27.9M | ||
| Q1 24 | $-48.4M | $7.9M |
| Q4 25 | 85.7% | 24.3% | ||
| Q3 25 | 88.5% | 25.9% | ||
| Q2 25 | 90.2% | 28.8% | ||
| Q1 25 | 90.7% | 24.1% | ||
| Q4 24 | 90.1% | 26.6% | ||
| Q3 24 | 90.6% | 27.4% | ||
| Q2 24 | 91.1% | 35.5% | ||
| Q1 24 | 87.7% | 28.7% |
| Q4 25 | 8.6% | 3.3% | ||
| Q3 25 | 20.3% | -3.5% | ||
| Q2 25 | -6.1% | 9.3% | ||
| Q1 25 | -6.3% | 4.1% | ||
| Q4 24 | 10.7% | 5.8% | ||
| Q3 24 | 15.3% | -1.7% | ||
| Q2 24 | 11.8% | 17.4% | ||
| Q1 24 | -25.1% | 8.2% |
| Q4 25 | 0.9% | 1.5% | ||
| Q3 25 | 10.2% | -4.0% | ||
| Q2 25 | -15.8% | 6.1% | ||
| Q1 25 | -17.3% | 1.8% | ||
| Q4 24 | 9.8% | 3.5% | ||
| Q3 24 | -4.8% | -2.1% | ||
| Q2 24 | -12.4% | 17.5% | ||
| Q1 24 | -43.9% | 5.7% |
| Q4 25 | $0.00 | $0.04 | ||
| Q3 25 | $0.06 | $-0.08 | ||
| Q2 25 | $-0.08 | $0.19 | ||
| Q1 25 | $-0.07 | $0.05 | ||
| Q4 24 | $0.05 | $0.10 | ||
| Q3 24 | $-0.02 | $-0.04 | ||
| Q2 24 | $-0.05 | $0.60 | ||
| Q1 24 | $-0.16 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $22.4M |
| Total DebtLower is stronger | $392.7M | — |
| Stockholders' EquityBook value | $274.2M | $363.2M |
| Total Assets | $949.9M | $548.6M |
| Debt / EquityLower = less leverage | 1.43× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $293.5M | $22.4M | ||
| Q3 25 | $263.8M | $18.0M | ||
| Q2 25 | $231.0M | $25.2M | ||
| Q1 25 | $250.6M | $26.7M | ||
| Q4 24 | $249.9M | $39.1M | ||
| Q3 24 | $249.8M | $35.5M | ||
| Q2 24 | $260.1M | $60.8M | ||
| Q1 24 | $239.6M | $47.4M |
| Q4 25 | $392.7M | — | ||
| Q3 25 | $392.0M | — | ||
| Q2 25 | $391.3M | — | ||
| Q1 25 | $390.7M | — | ||
| Q4 24 | $390.1M | — | ||
| Q3 24 | $389.5M | — | ||
| Q2 24 | $388.9M | — | ||
| Q1 24 | $388.4M | — |
| Q4 25 | $274.2M | $363.2M | ||
| Q3 25 | $230.4M | $364.4M | ||
| Q2 25 | $204.3M | $372.5M | ||
| Q1 25 | $193.6M | $366.9M | ||
| Q4 24 | $194.0M | $371.5M | ||
| Q3 24 | $178.8M | $380.0M | ||
| Q2 24 | $132.5M | $399.9M | ||
| Q1 24 | $130.7M | $376.4M |
| Q4 25 | $949.9M | $548.6M | ||
| Q3 25 | $868.8M | $554.6M | ||
| Q2 25 | $815.3M | $559.6M | ||
| Q1 25 | $789.8M | $578.9M | ||
| Q4 24 | $785.0M | $587.4M | ||
| Q3 24 | $786.6M | $571.3M | ||
| Q2 24 | $749.5M | $577.4M | ||
| Q1 24 | $721.8M | $570.6M |
| Q4 25 | 1.43× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.92× | — | ||
| Q1 25 | 2.02× | — | ||
| Q4 24 | 2.01× | — | ||
| Q3 24 | 2.18× | — | ||
| Q2 24 | 2.93× | — | ||
| Q1 24 | 2.97× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | $27.3M |
| Free Cash FlowOCF − Capex | $16.0M | $16.3M |
| FCF MarginFCF / Revenue | 8.6% | 13.1% |
| Capex IntensityCapex / Revenue | 0.2% | 8.8% |
| Cash ConversionOCF / Net Profit | 9.62× | 14.22× |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | $21.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.3M | $27.3M | ||
| Q3 25 | $35.7M | $-8.1M | ||
| Q2 25 | $-26.5M | $40.8M | ||
| Q1 25 | $7.8M | $-9.8M | ||
| Q4 24 | $-3.9M | $-7.4M | ||
| Q3 24 | $-23.0M | $-30.8M | ||
| Q2 24 | $22.7M | $43.7M | ||
| Q1 24 | $-29.7M | $25.2M |
| Q4 25 | $16.0M | $16.3M | ||
| Q3 25 | $35.3M | $-12.4M | ||
| Q2 25 | $-28.9M | $33.5M | ||
| Q1 25 | $7.5M | $-16.1M | ||
| Q4 24 | $-4.2M | $-10.7M | ||
| Q3 24 | $-23.3M | $-35.5M | ||
| Q2 24 | $21.6M | $38.2M | ||
| Q1 24 | $-31.5M | $7.0M |
| Q4 25 | 8.6% | 13.1% | ||
| Q3 25 | 20.9% | -14.6% | ||
| Q2 25 | -18.7% | 23.8% | ||
| Q1 25 | 6.0% | -13.9% | ||
| Q4 24 | -2.8% | -8.3% | ||
| Q3 24 | -16.5% | -40.2% | ||
| Q2 24 | 17.0% | 24.0% | ||
| Q1 24 | -28.5% | 5.1% |
| Q4 25 | 0.2% | 8.8% | ||
| Q3 25 | 0.2% | 5.0% | ||
| Q2 25 | 1.6% | 5.2% | ||
| Q1 25 | 0.2% | 5.4% | ||
| Q4 24 | 0.2% | 2.5% | ||
| Q3 24 | 0.3% | 5.3% | ||
| Q2 24 | 0.9% | 3.5% | ||
| Q1 24 | 1.6% | 13.2% |
| Q4 25 | 9.62× | 14.22× | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | 4.73× | ||
| Q1 25 | — | -4.68× | ||
| Q4 24 | -0.27× | -1.63× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.57× | ||
| Q1 24 | — | 3.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
SWBI
Segment breakdown not available.
